De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Knight Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Knight Therapeutics' is Samira Sakhia, benoemd in Aug2016, heeft een ambtstermijn van 8.17 jaar. bezit rechtstreeks 0.26% van de aandelen van het bedrijf, ter waarde CA$ 1.53M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 8.2 jaar.

Belangrijke informatie

Samira Sakhia

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.2yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17

Analyse CEO-vergoeding

Hoe is Samira Sakhia's beloning veranderd ten opzichte van Knight Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$21m
Mar 31 2024	n/a	n/a	-CA$17m
Dec 31 2023	n/a	n/a	-CA$17m
Sep 30 2023	n/a	n/a	-CA$8m
Jun 30 2023	n/a	n/a	-CA$16m
Mar 31 2023	n/a	n/a	-CA$15m
Dec 31 2022	CA$1m	CA$468k	-CA$30m
Sep 30 2022	n/a	n/a	-CA$23m
Jun 30 2022	n/a	n/a	-CA$33m
Mar 31 2022	n/a	n/a	-CA$7m
Dec 31 2021	CA$1m	CA$401k	CA$16m
Sep 30 2021	n/a	n/a	CA$32m
Jun 30 2021	n/a	n/a	CA$59m
Mar 31 2021	n/a	n/a	CA$47m
Dec 31 2020	CA$688k	CA$298k	CA$42m
Sep 30 2020	n/a	n/a	CA$27m
Jun 30 2020	n/a	n/a	CA$6m
Mar 31 2020	n/a	n/a	CA$8m
Dec 31 2019	CA$987k	CA$287k	CA$15m
Sep 30 2019	n/a	n/a	CA$21m
Jun 30 2019	n/a	n/a	CA$37m
Mar 31 2019	n/a	n/a	CA$22m
Dec 31 2018	CA$787k	CA$267k	CA$24m
Sep 30 2018	n/a	n/a	CA$31m
Jun 30 2018	n/a	n/a	CA$22m
Mar 31 2018	n/a	n/a	CA$18m
Dec 31 2017	CA$438k	CA$263k	CA$17m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Samira redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Canadian markt.

Compensatie versus inkomsten: De vergoeding van Samira is gestegen terwijl het bedrijf verliesgevend is.

CEO

Samira Sakhia (56 yo)

8.2yrs

Tenure

CA$1,166,767

Compensatie

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Goodman	Executive Chairman	11.8yrs	CA$438.93k	0.95% CA$ 5.6m
Samira Sakhia	President	8.2yrs	CA$1.17m	0.26% CA$ 1.5m
Arvind Utchanah	Chief Financial Officer	4.6yrs	CA$801.68k	0.042% CA$ 244.9k
Amal Khouri	Chief Business Officer	3.6yrs	CA$719.09k	0.16% CA$ 916.3k
Jeff Martens	Global Vice President of Commercial	4yrs	CA$534.15k	geen gegevens
Stephani Saverio	Vice President of Business Development	3.5yrs	CA$550.38k	geen gegevens
Leopoldo Bosano	Vice-President of Manufacturing & Operations	2.6yrs	geen gegevens	geen gegevens
Monica Percario	Global Vice President of Scientific Affairs	no data	geen gegevens	geen gegevens
Henrique Dias	Global Director of Marketing	1.8yrs	geen gegevens	0.0026% CA$ 15.2k
Susan Emblem	Global Vice President of Human Resources	3.2yrs	geen gegevens	0.020% CA$ 119.7k
Melanie Groleau	Global Vice President of Medical & Clinical	less than a year	geen gegevens	0.0030% CA$ 17.8k

3.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van GUD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Goodman	Executive Chairman	11.8yrs	CA$438.93k	0.95% CA$ 5.6m
Samira Sakhia	President	8.2yrs	CA$1.17m	0.26% CA$ 1.5m
James Gale	Independent Lead Director	11.8yrs	CA$155.00k	0.052% CA$ 305.5k
Robert Lande	Independent Director	10.8yrs	CA$133.83k	0.24% CA$ 1.4m
Nicolas Sujoy	Independent Director	4.3yrs	CA$125.58k	0.012% CA$ 68.8k
Janice Murray	Independent Director	4.3yrs	CA$122.50k	0.0084% CA$ 49.5k
Michael Tremblay	Independent Director	5.4yrs	CA$115.00k	0.0020% CA$ 11.7k

8.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GUD wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

Knight Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Independent Director recently sold CA$148k worth of stock

Executive Chairman exercised options to buy CA$543k worth of stock.

President exercised options to buy CA$309k worth of stock.

Knight Therapeutics Inc., Annual General Meeting, May 08, 2024

Executive Chairman recently bought CA$111k worth of stock

Insufficient new directors

Recent updates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Knight Therapeutics Inc. Revises Earnings Guidance for the Year 2024

Knight Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024

Independent Director recently sold CA$148k worth of stock

Executive Chairman exercised options to buy CA$543k worth of stock.

Price target increased by 7.3% to CA$7.24

Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: CA$0.045 loss per share (vs CA$0.035 loss in 1Q 2023)

Knight Therapeutics Inc. to Report Q1, 2024 Results on May 09, 2024

President exercised options to buy CA$309k worth of stock.

Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.26 loss in FY 2022)

Knight Therapeutics Inc. to Report Q4, 2023 Results on Mar 21, 2024

Knight Therapeutics Inc., Annual General Meeting, May 08, 2024

Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q3, 2023 Results on Nov 09, 2023

Knight Therapeutics Inc. Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil

United Medical Ltd. Announces Regulatory Submission of Pemigatinib in Brazil

Executive Chairman recently bought CA$111k worth of stock

Knight Therapeutics Inc. Updates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q2, 2023 Results on Aug 10, 2023

Insufficient new directors

President recently bought CA$95k worth of stock

Knight Therapeutics Inc. Updates Revenue Guidance for the Fiscal 2023

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.16 loss in 1Q 2022)

Knight Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 309%

Price target decreased by 12% to CA$6.30

Knight Therapeutics Inc. Announces Relaunch of AKYNZEO in Canada

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. Reports Impairment of Intangible Assets for the Third Quarter Ended September 30, 2022

Knight Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Executive Chairman recently bought CA$135k worth of stock

Executive Chairman recently bought CA$104k worth of stock

Executive Chairman recently bought CA$207k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022

Knight Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to CA$6.86

Independent Director recently bought CA$89k worth of stock

President recently bought CA$104k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Knight Therapeutics Inc., Annual General Meeting, May 11, 2022

Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia

Executive Chairman recently bought CA$102k worth of stock

Executive Chairman recently bought CA$102k worth of stock

Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia

President recently bought CA$82k worth of stock

Executive Chairman recently bought CA$105k worth of stock

Executive Chairman recently bought CA$95k worth of stock

Third quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.14 profit in 3Q 2020)

High number of new directors

High number of new directors

Executive Chairman recently bought CA$105k worth of stock

CEO & Director recently bought CA$202k worth of stock

Consensus EPS estimates increase to CA$0.28

Second quarter 2021 earnings released: EPS CA$0.23 (vs CA$0.13 in 2Q 2020)

CEO & Director recently bought CA$94k worth of stock

CEO & Director recently bought CA$189k worth of stock

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?